Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Ningshao Xia, Chunlan Zhuang et al.|The Lancet Respiratory Medicine|2022Cited by 140
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trialYuemei Hu, Ningshao Xia, Yafei Li et al.|Science Bulletin|2023Cited by 26
Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C MiceLi Zhang, Yuemei Hu, Yin Chen et al.|Viruses|2015Cited by 14